Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

TOXICITY OF COUMARIN

L. W. Hazleton, T. W. Tusing, B. R. Zeitlin, R. Thiessen Jr. and H. K. Murer
Journal of Pharmacology and Experimental Therapeutics November 1956, 118 (3) 348-358;
L. W. Hazleton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. W. Tusing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. R. Zeitlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Thiessen Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. K. Murer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The acute oral LD50 of coumarin in propylene glycol for male albino rats was calcualted at 0.29 gm./kgm ± 0.03 mgm./kgnm.; the acute oral LD50 of coumarin in corn oil for male albino rats was calculated at 0.52 gm./kgm. ± 0.03 gm./kgm.

Ad libitum feeding of coumarin to male albino rats at levels of 200 parts per million and 1000 parts parts per million (ppm), for 90 days, reduced growth but produced no deaths, and no histopathological liver or kidney changs. Organ weights of the livers, kidneys, spleens, and testes obtained at autopsy from the test animals were comparable to those of the controls.

Coumarin incorporated in the diet of male and femal albino rats for a 90-day period at levels of 50 ppm, 250 ppm, and 2500 ppm, and fed in mutually pair-fed diets, elicited no significant untoward nutritional effects at the two lower levels, as measured by weight gains or food efficiency; significant supression in food efficiency was produced by the 2500 ppm level. Gross and microscopic liver pathology and increased liver weights were produced at the 2500 ppm dietary level but not at the lower levels.

Coumarin, administered to dogs for time intervals ranging from eight to nineteen days in oral doses of 100 mgm./kgm./day in powdered form or dissolved as a 4.0 per cent solutin in propylene glycol, produed deficinite liver damage as evidence by the clinical observations, biochemical studies, and gross amid microscopic pathology. Two dogs followed for a period of 40 to 61 days after receiving the last oral dose of coumarimi at 100 mgm./kgm/day were found to have recovered from the toxic manifestations of eoumarin as evidenced by gross signs and laboratory studies. Autopsy findings were without evident gross pathology, and histological examination revealed the initially damaged liver tissue to be under going the processes of healimg and repair.

The suitability of coumarin for sustained use as a flavor additive for foods and pharmaceuticals cannot be defined properly, soley on the basis of the acute and subacute toxicity studies herein reported. These studies of a short-term nature make apparent, however, the need for long-term feeding studies to determine a safe upper limit of use, if any, for the compound.

Footnotes

    • Received June 16, 1956.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 118, Issue 3
1 Nov 1956
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
TOXICITY OF COUMARIN
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

TOXICITY OF COUMARIN

L. W. Hazleton, T. W. Tusing, B. R. Zeitlin, R. Thiessen and H. K. Murer
Journal of Pharmacology and Experimental Therapeutics November 1, 1956, 118 (3) 348-358;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

TOXICITY OF COUMARIN

L. W. Hazleton, T. W. Tusing, B. R. Zeitlin, R. Thiessen and H. K. Murer
Journal of Pharmacology and Experimental Therapeutics November 1, 1956, 118 (3) 348-358;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Meeting Report for the ASPET–Ray Fuller Symposium: Cellular Mechanisms and Novel Strategies for Pain Control
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics